Praxis Precision Medicines (NASDAQ:PRAX) Announces Quarterly Earnings Results, Beats Estimates By $0.38 EPS

Praxis Precision Medicines (NASDAQ:PRAX) announced its quarterly earnings data on Thursday. The company reported ($3.20) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.38, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• NDAs accepted for ulixacaltamide and relutrigine with PDUFA dates set (ulixacaltamide: Jan 29; relutrigine: Sep 27), and the company is scaling its commercial organization, distribution and payer/access efforts ahead of potential U.S. launches.
• Enrollment for the EMERALD study is complete and top-line results are expected in Q4; a positive readout could support a supplemental NDA to expand relutrigine into the broader DEE population (~200,000 U.S. patients), materially increasing commercial potential.
• EMBRAVE Part A data for the Solidus ASO elsunersen showed a 77% placebo?adjusted reduction in monthly seizures and signs of disease?modifying benefit in SCN2A early?onset DEE with a generally favorable tolerability profile.
• The vormatrigine program has near?term catalysts — POWER1 readout later this quarter and ongoing POWER2/POWER3 studies — and management reports encouraging blinded safety data and expectation of meaningful efficacy across flexible 20/30/40 mg dosing.
• Q1 financials showed operating expenses of ~$106M and $86M of cash used (up versus prior year) but a strengthened cash balance of ~$1.4B after a January follow?on offering, which management says funds operations into 2028.

Praxis Precision Medicines Stock Performance

NASDAQ:PRAX traded down $4.79 during trading hours on Thursday, hitting $333.28. The stock had a trading volume of 457,694 shares, compared to its average volume of 461,717. Praxis Precision Medicines has a one year low of $35.21 and a one year high of $356.00. The company has a market cap of $9.29 billion, a price-to-earnings ratio of -24.76 and a beta of 2.76. The business’s 50 day moving average is $317.97 and its 200-day moving average is $276.55.

Wall Street Analysts Forecast Growth

PRAX has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $1,245.00 price objective on shares of Praxis Precision Medicines in a report on Tuesday, April 7th. TD Cowen restated a “buy” rating on shares of Praxis Precision Medicines in a report on Thursday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $510.00 target price on shares of Praxis Precision Medicines in a research note on Tuesday, April 14th. Wells Fargo & Company set a $305.00 target price on shares of Praxis Precision Medicines and gave the company an “equal weight” rating in a research note on Friday, February 20th. Finally, Truist Financial raised shares of Praxis Precision Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Five equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $590.78.

Institutional Investors Weigh In On Praxis Precision Medicines

Several large investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. increased its position in shares of Praxis Precision Medicines by 13.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company’s stock worth $83,031,000 after acquiring an additional 231,827 shares in the last quarter. Orbis Allan Gray Ltd acquired a new stake in shares of Praxis Precision Medicines during the fourth quarter worth $369,946,000. Morgan Stanley raised its holdings in shares of Praxis Precision Medicines by 38.3% during the fourth quarter. Morgan Stanley now owns 889,889 shares of the company’s stock worth $262,286,000 after acquiring an additional 246,394 shares during the period. Deerfield Management Company L.P. raised its holdings in shares of Praxis Precision Medicines by 22.4% during the third quarter. Deerfield Management Company L.P. now owns 840,851 shares of the company’s stock worth $44,565,000 after acquiring an additional 153,920 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Praxis Precision Medicines by 12.7% during the third quarter. Bank of America Corp DE now owns 482,861 shares of the company’s stock worth $25,592,000 after acquiring an additional 54,458 shares during the period. Institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.